HRP20211043T1 - Derivati 6,7-dihidro-5h-benzo[7]anulena kao modulatori estrogenskih receptora - Google Patents

Derivati 6,7-dihidro-5h-benzo[7]anulena kao modulatori estrogenskih receptora Download PDF

Info

Publication number
HRP20211043T1
HRP20211043T1 HRP20211043TT HRP20211043T HRP20211043T1 HR P20211043 T1 HRP20211043 T1 HR P20211043T1 HR P20211043T T HRP20211043T T HR P20211043TT HR P20211043 T HRP20211043 T HR P20211043T HR P20211043 T1 HRP20211043 T1 HR P20211043T1
Authority
HR
Croatia
Prior art keywords
group
formula
substituted
unsubstituted
pharmaceutically acceptable
Prior art date
Application number
HRP20211043TT
Other languages
English (en)
Inventor
Monsif Bouaboula
Maurice Brollo
Victor Certal
Youssef El-Ahmad
Bruno FILOCHE-ROMMÉ
Frank Halley
Gary Mccort
Laurent Schio
Michel Tabart
Corinne Terrier
Fabienne Thompson
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of HRP20211043T1 publication Critical patent/HRP20211043T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Claims (14)

1. Spoj s formulom (I): [image] naznačen time što: - R1 i R2 predstavljaju neovisno vodikov atom ili atom deuterija; - R3 predstavlja vodikov atom , skupinu -COOH, skupinu -OH ili skupinu -OPO(OH)2 ; - R4 predstavlja vodikov atom ili fluorov atom; - R5 predstavlja vodikov atom ili skupinu -OH; - pri čemu: ∘ najmanje jedan od R3 ili R5 se razlikuje od vodikovog atoma; ∘ kada R3 predstavlja -COOH skupinu, -OH skupinu ili -OPO(OH)2 skupinu, tada R5 predstavlja vodikov atom; ∘ kada R5 predstavlja -OH skupinu, tada R3 i R4 predstavljaju vodikove atome; - R6 je odabran od: ▪ fenilne skupine ili heteroarilne skupine koja sadrži 3 do 9 atoma ugljika i sadrži 1 do 3 heteroatoma neovisno odabrana od kisika, dušika i sumpora, pri čemu su navedene fenilne i heteroarilne skupine nesupstituirane ili supstituirane s 1 do 3 supstituenta neovisno odabranih iz niza koji čine: (C1-C6)-alkil skupina nesupstituirana ili supstituirana s jednim ili više fluorovih atoma; halogeni atom; -OH skupina; (C1-C6)-alkoksi skupina nesupstituirana ili supstituirana s jednim ili više fluorovih atoma; cijano skupina; sumporna skupina supstituirana s 5 fluorovih atoma ili (C1-C6)-alkil skupine supstituirane s dva ili više fluorovih atoma; sulfonil-(C1-C6)-alkil skupina pri čemu je navedena (C1-C6)-alkil skupina nesupstituirana ili supstituirana s dva ili više fluorovih atoma; silanska skupina supstituirana sa 3 skupine (C1-C6)-alkil; aminska skupina nesupstituirana ili supstituirana s jednom ili više skupina (C1-C6)-alkil; amidna skupina nesupstituirana ili supstituirana s jednom ili više skupina (C1-C6)-alkil; heterocikloalkilne skupine zasićene ili djelomično zasićene, koje sadrže 3 do 5 atoma ugljika i sadrže 1 ili 2 heteroatoma neovisno odabrana između kisika, dušika ili sumpora, ili heteroarilna skupina koja sadrži 2 do 4 atoma ugljika i koja sadrži 1 do 3 heteroatoma odabrana između kisika, dušika ili sumpora i koja je nesupstituirana ili supstituirana s okso skupinom; ▪ cikloalkilna skupina ili heterocikloalkilna skupina koja sadrži 4 do 9 atoma ugljika i koja sadrži 1 ili 2 heteroatoma neovisno odabrana između kisika, dušika ili sumpora, navedene cikloalkilne skupine ili heterocikloalkilne skupine su zasićene ili djelomično zasićene i nesupstituirane ili supstituirane s 1 do 4 supstituenta neovisno odabrana od: fluorovog atoma; skupine -OH; skupine (C1-C6)-alkil; skupine -COOR7 pri čemu R7 je skupina (C1-C6)-alkil; ili okso skupina; ili njegova farmaceutski prihvatljiva sol.
2. Spoj s formulom (I) prema patentnom zahtjevu 1, naznačen time što je R6 odabran od fenilne skupine nesupstituirane ili supstituirane s 1 do 3 supstituenata neovisno odabrana iz niza koji čine: skupina (C1-C6)-alkil nesupstituirana ili supstituirana s jednim ili više fluorovih atoma; halogeni atom; -OH skupina; (C1-C6)-alkoksi skupina nesupstituirana ili supstituirana s jednim ili više fluorovih atoma; cijano skupina; sumporna skupina supstituirana s 5 fluorovih atoma ili (C1-C6)-alkilne skupine supstituirane s dva ili više fluorovih atoma; sulfonil-(C1-C6)-alkil skupina pri čemu je navedena skupina (C1-C6)-alkil nesupstituirana ili supstituirana s dva ili više fluorovih atoma; silanska skupina supstituirana sa 3 skupine (C1-C6)-alkil; aminska skupina nesupstituirana ili supstituirana s jednom ili više skupina (C1-C6)-alkil; amidna skupina nesupstituirana ili supstituirana s jednom ili više skupina (C1-C6)-alkil; heterocikloalkilna skupina zasićena ili djelomično zasićena, koja sadrži 3 do 5 ugljikovih atoma i sadrži 1 ili 2 heteroatoma neovisno odabrana između kisika, dušika ili sumpora, ili heteroarilna skupina koja sadrži 2 do 4 ugljikova atoma i i koja sadrži 1 do 3 heteroatoma odabrana između kisika, dušika ili sumpora i koja je nesupstituirana ili supstituirana s okso skupinom; ili njegova farmaceutski prihvatljiva sol.
3. Spoj s formulom (I) prema patentnom zahtjevu 1 ili 2, naznačen time što je R6 odabran od fenilne skupine nesupstituirane ili supstituirane s 1 do 3 supstituenta neovisno odabrana iz niza koji čine metilna skupina; etilna skupina; izopropilna skupina; terc-butilna skupina; -CHF2 skupina; -CF3 skupina; -CF2CH3 skupina; klorov atom; fluorov atom; -OH skupina; -OCH3 skupina; -OCH2CH3 skupina; -OCH2CH2F skupina; -OCHF2 skupina; -OCH2CHF2 skupina; -OCF3 skupina; -OCH2CF3 skupina; cijano skupina; -SCHF2 skupina; -SCF3 skupina; -SF5 skupina; -SO2CH3 skupina; -SO2CF3 skupina; -Si(CH3)3 skupina; oksetanska skupina; piperidinska skupina; morfolinska skupina; pirolidinska skupina ili triazolonska skupina; ili njegova farmaceutski prihvatljiva sol.
4. Spoj s formulom (I) prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što R3 je -COOH skupina ili -OH skupina; ili njegova farmaceutski prihvatljiva sol.
5. Spoj s formulom (I) prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time što je spoj 5-[4-[(3S)-1-(3-fluoropropil)pirolidin-3-il]oksifenil]-6-(1H-indol-5-il)-8,9-dihidro-7H-benzo[7]anulen-3-ol s formulom [image] 5-[4-[(3S)-1-(3-fluoropropil)pirolidin-3-il]oksifenil]-6-indolin-5-il-8,9-dihidro-7H-benzo[7]anulen-2-ol s formulom [image] 5-[4-[(3S)-1-(3-fluoropropil)pirolidin-3-il]oksifenil]-6-(1,2,3,6-tetrahidropiridin-4-il)-8,9-dihidro-7H-benzo[7]anulen-2-ol s formulom [image] 6-(2,4-diklorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirolidin-3-il]oksifenil]-8,9-dihidro-7H-benzo[7]anulen-2-karboksilna kiselina s formulom [image] 5-[4-[(3S)-1-(3-fluoropropil)pirolidin-3-il]oksifenil]-6-[4-(trifluorometoksi)fenil]-8,9-dihidro-7H-benzo[7]anulen-2-ol s formulom [image] 6-(6-etoksi-2-fluoro-3-piridil)-1-fluoro-5-[4-[(3S)-1-(3-fluoropropil)pirolidin-3-il]oksifenil]-8,9-dihidro-7H-benzo[7]anulen-2-ol s formulom [image] 6-(2-etoksipirimidin-5-il)-5-[4-[(3S)-1-(3-fluoropropil)pirolidin-3-il]oksifenil]-8,9-dihidro-7H-benzo[7]anulen-2-ol s formulom [image] [5-[4-[(3S)-1-(3-fluoropropil)pirolidin-3-il]oksifenil]-6-[4-(trifluorometoksi)fenil]-8,9-dihidro-7H-benzo[7]anulen-2-il] dihidrogen fosfat s formulom [image] ili 5-[4-[(3S)-1-(3-fluoropropil)pirolidin-3-il]oksifenil]-6-(4-hidroksicikloheksil)-8,9-dihidro-7H-benzo[7]anulen-2-ol s formulom [image] ili njihova farmaceutski prihvatljiva sol.
6. Spojevi odabrani iz sljedećih formula: [image] [image] pri čemu R3, R4, R5 i R6 su kako je definirano u formuli (I) prema bilo kojem od patentnih zahtjeva 1 do 4.
7. Lijek, naznačen time što sadrži spoj s formulom (I) prema bilo kojem od patentnih zahtjeva 1 do 5, ili njegovu farmaceutski prihvatljivu sol.
8. Farmaceutski pripravak, naznačen time što sadrži spoj s formulom (I) prema bilo kojem od patentnih zahtjeva 1 do 5, ili njegovu farmaceutski prihvatljivu sol, te najmanje jednu farmaceutski prihvatljivu pomoćnu tvar.
9. Spoj s formulom (I) prema bilo kojem od patentnih zahtjeva 1 do 5, ili njegova farmaceutski prihvatljiva sol, naznačen time što je za uporabu u liječenju ovulacijske disfunkcije, raka, endometrioze, osteoporoze, benigne hipertrofije prostate ili upale.
10. Spoj s formulom (I), ili njegova farmaceutski prihvatljiva sol, za upotrebu prema patentnom zahtjevu 9 naznačen time što je za liječenje raka.
11. Spoj s formulom (I), ili njegova farmaceutski prihvatljiva sol, za upotrebu prema patentnom zahtjevu 10, naznačen time što je rak rak ovisan o estrogenom receptoru.
12. Spoj s formulom (I), ili njegova farmaceutski prihvatljiva sol, za upotrebu prema patentnom zahtjevu 10 ili 11, naznačen time što je rak odabran od karcinoma dojke, jajnika, endometrija, prostate, maternice, vrata maternice i pluća ili njihovih metastaza.
13. Spoj s formulom (I), ili njegova farmaceutski prihvatljiva sol, za upotrebu prema patentnom zahtjevu 12, naznačen time što je metastaza cerebralna metastaza.
14. Spoj s formulom (I), ili njegova farmaceutski prihvatljiva sol, za upotrebu prema patentnom zahtjevu 12, naznačen time što je rak otporan na anti-hormonsko liječenje.
HRP20211043TT 2016-02-15 2021-06-30 Derivati 6,7-dihidro-5h-benzo[7]anulena kao modulatori estrogenskih receptora HRP20211043T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305174 2016-02-15
PCT/EP2017/053282 WO2017140669A1 (en) 2016-02-15 2017-02-14 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators
EP17705842.7A EP3416962B1 (en) 2016-02-15 2017-02-14 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators

Publications (1)

Publication Number Publication Date
HRP20211043T1 true HRP20211043T1 (hr) 2021-10-01

Family

ID=55398242

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211043TT HRP20211043T1 (hr) 2016-02-15 2021-06-30 Derivati 6,7-dihidro-5h-benzo[7]anulena kao modulatori estrogenskih receptora

Country Status (37)

Country Link
US (6) US9714221B1 (hr)
EP (2) EP3524600B1 (hr)
JP (4) JP6425852B1 (hr)
KR (2) KR20220098057A (hr)
CN (2) CN112979524A (hr)
AR (1) AR107616A1 (hr)
AU (2) AU2017221083B2 (hr)
BR (1) BR112018016490A2 (hr)
CA (1) CA3014424A1 (hr)
CL (1) CL2018002290A1 (hr)
CO (1) CO2018009534A2 (hr)
CR (1) CR20180442A (hr)
CY (1) CY1125165T1 (hr)
DK (2) DK3524600T3 (hr)
DO (1) DOP2018000184A (hr)
EA (2) EA038639B1 (hr)
EC (1) ECSP18069466A (hr)
ES (2) ES2906208T3 (hr)
HR (1) HRP20211043T1 (hr)
HU (2) HUE055107T2 (hr)
IL (2) IL261099B (hr)
LT (1) LT3416962T (hr)
MA (2) MA46479A (hr)
MX (2) MX2020011469A (hr)
MY (1) MY196486A (hr)
PE (1) PE20181893A1 (hr)
PH (1) PH12018501679A1 (hr)
PL (1) PL3416962T3 (hr)
PT (1) PT3416962T (hr)
RS (1) RS62132B1 (hr)
SG (2) SG11201806829TA (hr)
SI (1) SI3416962T1 (hr)
TN (1) TN2018000285A1 (hr)
TW (3) TWI737681B (hr)
UY (1) UY37124A (hr)
WO (1) WO2017140669A1 (hr)
ZA (1) ZA201805137B (hr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6425852B1 (ja) * 2016-02-15 2018-11-21 サノフイＳａｎｏｆｉ エストロゲン受容体調節剤としての６，７−ジヒドロ−５ｈ−ベンゾ［７］アヌレン誘導体
WO2018091153A1 (en) * 2016-11-17 2018-05-24 Sanofi Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
AU2018217809A1 (en) 2017-02-10 2019-08-22 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
US11759450B2 (en) 2018-02-06 2023-09-19 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
AU2019321588A1 (en) 2018-08-17 2021-03-04 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
MX2021002666A (es) * 2018-09-07 2021-07-16 Sanofi Sa Proceso para la preparacion de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-( 3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]a nulen-2-carboxilato de metilo.
EP3699167A1 (en) * 2019-02-22 2020-08-26 Sanofi Process for preparing methyl 1-benzosuberone-7-carboxylate
JP2022531898A (ja) 2019-05-09 2022-07-12 サノフイ 転移性または進行性乳房がん患者において使用するための６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸
KR102058384B1 (ko) * 2019-09-06 2019-12-24 강원대학교산학협력단 2h-벤조[7]에눌렌 화합물 및 이의 제조방법
JP2022552132A (ja) 2019-10-01 2022-12-15 サノフイ 新規の置換６，７－ジヒドロ－５ｈ－ベンゾ［７］アンヌレン化合物、その製造方法およびその治療的使用
CA3160897A1 (en) * 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) * 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
CN113896669A (zh) * 2020-06-22 2022-01-07 江苏先声药业有限公司 雌激素受体调节剂及其用途
JP7419575B2 (ja) 2020-06-28 2024-01-22 メッドシャイン ディスカバリー インコーポレイテッド 縮合環インダゾール系化合物
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
KR20230095996A (ko) 2020-10-19 2023-06-29 사노피 치환 6,7-디히드로-5h-벤조[7]아눌렌 화합물 및 이의 유도체, 이의 제조 방법 및 이의 치료적 용도
JP2023551192A (ja) 2020-11-23 2023-12-07 サノフイ 乳がんにおける内分泌療法のモニタリングに使用するためのｅｒ制御遺伝子のパネル
IL303041A (en) * 2020-11-23 2023-07-01 Sanofi Sa Combinations containing abamciclib, and 6-(2,4-DICHLOROPHENYL)-5-[4-[(3S)-1-(3-FLUOROPROPYL)PYRROLIDIN-3-YL]OXYPHENYL]-8,9-DIHYDRO-7H-BENZO [7]ANNULENE-2-CARBOXYLIC ACID
US20240132482A1 (en) * 2021-02-04 2024-04-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Benzo seven-membered ring bifunctional compound and application thereof
TW202304424A (zh) 2021-04-12 2023-02-01 法商賽諾菲公司 包含依維莫司和安森司群的組合
TW202304425A (zh) 2021-04-12 2023-02-01 法商賽諾菲公司 包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合
TW202313558A (zh) * 2021-07-08 2023-04-01 大陸商勤浩醫藥(蘇州)有限公司 一類苯并七元環類化合物及其應用
WO2023287938A1 (en) 2021-07-15 2023-01-19 Teva Pharmaceuticals International Gmbh Solid state forms of amcenestrant
WO2023125700A1 (zh) * 2021-12-28 2023-07-06 南京明德新药研发有限公司 四氢环庚吲唑化合物的盐型、晶型
TW202400136A (zh) 2022-03-13 2024-01-01 法商賽諾菲公司 以安森司群(amcenestrant)治療乳癌
WO2023187086A1 (en) 2022-03-31 2023-10-05 Sanofi Amorphous solid form of amcenestrant
WO2023198901A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted 4-amino-4-oxo-but-2-enyl derivatives, processes for their preparation and therapeutic uses thereof
WO2023198879A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
WO2023198904A1 (en) 2022-04-15 2023-10-19 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene derivatives, processes for their preparation and therapeutic uses thereof
WO2023198907A1 (en) 2022-04-15 2023-10-19 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene derivatives, processes for their preparation and therapeutic uses thereof
WO2023198905A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated vinyl-n-propyl-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
WO2023198903A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine and n‑propyl-azetidine compounds, processes for their preparation and therapeutic uses thereof
WO2024006776A1 (en) * 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
WO2024042163A1 (en) 2022-08-25 2024-02-29 Sanofi Novel substituted 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof
WO2024042157A1 (en) 2022-08-25 2024-02-29 Sanofi Novel substituted quinoline and tetrahydronaphthalene carboxylic acid derivatives and therapeutic uses thereof
WO2024042152A1 (en) 2022-08-25 2024-02-29 Sanofi Novel substituted 2-carbonyl-benzothiophene-6- carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof
WO2024042187A1 (en) 2022-08-25 2024-02-29 Sanofi Novel substituted benzothiophene-6-carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof
WO2024042185A1 (en) 2022-08-25 2024-02-29 Sanofi Novel substituted tetrahydroisoquinoline-6- carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof.
WO2024052518A1 (en) 2022-09-09 2024-03-14 Sanofi Substituted tetrahydrocyclohepta[e]indole derivatives, processes for their preparation and therapeutic uses thereof
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015579A1 (en) * 1991-03-08 1992-09-17 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
DE19833786A1 (de) * 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
EP1229036B1 (en) 2001-01-24 2005-01-12 CHIESI FARMACEUTICI S.p.A. 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
WO2003016270A2 (en) * 2001-08-11 2003-02-27 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
DK1501819T3 (da) 2002-04-24 2011-01-10 Merck Sharp & Dohme Østrogenreceptormodulatorer
JP4500689B2 (ja) * 2002-12-26 2010-07-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的エストロゲン受容体モジュレーター
AU2004268455B2 (en) * 2003-08-29 2009-12-17 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
CA2571587C (en) * 2004-06-25 2013-02-12 Janssen Pharmaceutica, N.V. Quaternary salt ccr2 antagonists
US20050288238A1 (en) * 2004-06-28 2005-12-29 Pfizer Inc Benzocyclodecane derivatives with antitumor activity
DE102005014090A1 (de) * 2005-03-22 2006-09-28 Schering Ag 5H-Benzocycloheptenderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
JP5354775B2 (ja) * 2005-06-14 2013-11-27 ベイラー ユニバーシティ チューブリン結合活性を有するコンブレタスタチンアナログ
EP2048126A1 (de) * 2007-10-11 2009-04-15 Bayer Schering Pharma AG Benzocycloheptanderivate als selektiv wirksame Estrogene
EP2090579A1 (en) * 2008-01-29 2009-08-19 Sanofi-Aventis Substituted heteroarylamide diazepinopyrimidone derivatives
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
WO2012068284A2 (en) * 2010-11-16 2012-05-24 Baylor University Efficient method for preparing functionalized benzosuberenes
TW201329025A (zh) * 2011-11-01 2013-07-16 Astex Therapeutics Ltd 醫藥化合物
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN102584687A (zh) 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
CA2861939A1 (en) * 2011-12-30 2013-07-04 Centaurus Biopharma Co., Ltd. Novel arylalkene derivatives and use thereof as selective estrogen receptor modulators
KR20150119926A (ko) * 2013-02-19 2015-10-26 바이엘 파마 악티엔게젤샤프트 비시클로 2,3-벤조디아제핀 및 스피로시클릭 치환된 2,3-벤조디아제핀
WO2015028409A1 (de) * 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2016097072A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
EP3233828B1 (en) 2014-12-18 2020-03-04 F. Hoffmann-La Roche AG Estrogen receptor modulators and uses thereof
IL255148B2 (en) 2015-04-29 2023-04-01 Radius Pharmaceuticals Inc 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation
CN106924210A (zh) 2015-12-29 2017-07-07 北京新领先医药科技发展有限公司 一种含有帕布昔利布的胶囊剂及其制备方法
JP6425852B1 (ja) * 2016-02-15 2018-11-21 サノフイＳａｎｏｆｉ エストロゲン受容体調節剤としての６，７−ジヒドロ−５ｈ−ベンゾ［７］アヌレン誘導体
WO2018091153A1 (en) 2016-11-17 2018-05-24 Sanofi Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof

Also Published As

Publication number Publication date
JP6425852B1 (ja) 2018-11-21
US20240150284A1 (en) 2024-05-09
LT3416962T (lt) 2021-07-12
TWI737681B (zh) 2021-09-01
CR20180442A (es) 2018-12-21
US20210323916A1 (en) 2021-10-21
US20170233340A1 (en) 2017-08-17
EA201891841A1 (ru) 2019-01-31
HUE055107T2 (hu) 2021-10-28
EA202090255A2 (ru) 2020-05-31
CN108884079B (zh) 2021-03-05
DK3524600T3 (da) 2022-02-07
US11214541B2 (en) 2022-01-04
CL2018002290A1 (es) 2018-10-05
MA44226B1 (fr) 2021-07-29
JP6695457B2 (ja) 2020-05-20
SG11201806829TA (en) 2018-09-27
CO2018009534A2 (es) 2018-09-20
EP3524600A1 (en) 2019-08-14
AU2021225215B2 (en) 2023-05-25
KR20220098057A (ko) 2022-07-08
JP2019031537A (ja) 2019-02-28
WO2017140669A1 (en) 2017-08-24
CA3014424A1 (en) 2017-08-24
CY1125165T1 (el) 2023-06-09
MX2018009908A (es) 2018-09-07
ECSP18069466A (es) 2018-09-30
SI3416962T1 (sl) 2021-08-31
IL261099A (en) 2018-10-31
TW201741285A (zh) 2017-12-01
EP3416962B1 (en) 2021-05-05
BR112018016490A2 (pt) 2018-12-18
TN2018000285A1 (en) 2020-01-16
PT3416962T (pt) 2021-07-23
JP2019081776A (ja) 2019-05-30
PE20181893A1 (es) 2018-12-11
TWI779621B (zh) 2022-10-01
ES2881508T3 (es) 2021-11-29
RS62132B1 (sr) 2021-08-31
MY196486A (en) 2023-04-17
IL277750B (en) 2022-06-01
CN108884079A (zh) 2018-11-23
TW202138349A (zh) 2021-10-16
US20180079720A1 (en) 2018-03-22
UY37124A (es) 2017-09-29
PL3416962T3 (pl) 2021-11-22
IL261099B (en) 2020-10-29
EA038639B1 (ru) 2021-09-28
EA202090255A3 (ru) 2020-07-31
IL277750A (en) 2020-11-30
EA034994B1 (ru) 2020-04-15
DK3416962T3 (da) 2021-07-26
JP6476343B2 (ja) 2019-02-27
US10570090B2 (en) 2020-02-25
EP3524600B1 (en) 2021-11-17
ZA201805137B (en) 2023-09-27
ES2906208T3 (es) 2022-04-13
US20200392081A1 (en) 2020-12-17
CN112979524A (zh) 2021-06-18
JP6868142B2 (ja) 2021-05-12
US9714221B1 (en) 2017-07-25
DOP2018000184A (es) 2019-01-31
MA46479A (fr) 2019-08-14
HUE057892T2 (hu) 2022-06-28
PH12018501679A1 (en) 2019-06-10
AU2017221083B2 (en) 2021-06-24
KR20180105759A (ko) 2018-09-28
AU2021225215A1 (en) 2021-09-30
EP3416962A1 (en) 2018-12-26
JP2018537406A (ja) 2018-12-20
SG10202106024XA (en) 2021-07-29
US20220073460A1 (en) 2022-03-10
AU2017221083A1 (en) 2018-10-04
AR107616A1 (es) 2018-05-16
TW202138348A (zh) 2021-10-16
JP2020128385A (ja) 2020-08-27
MX2020011469A (es) 2021-09-30
TWI779620B (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
HRP20211043T1 (hr) Derivati 6,7-dihidro-5h-benzo[7]anulena kao modulatori estrogenskih receptora
RU2019118460A (ru) Новые соединения замещенного n-(3-фторпропил)пирролидина, способы их получения и их терапевтическое применение
CY1120559T1 (el) Παραγωγα 1-(ακετυλ)-πιπεριδινης και 1-(ακετυλ)-πιπεραζινης ως μυκητοκτονα για χρηση στη φυτοπροστασια
EA200900658A1 (ru) Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами
MX2010006421A (es) Compuestos organicos.
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
CY1115175T1 (el) Ενωσεις 9-υποκατεστημενης-8-οξο-αδενινης ως ρυθμιστες υποδοχεων τυπου toll (tlr7)
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
MY139941A (en) Indole derivatives
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
BR112012026951A2 (pt) Compostos de amino-piridazinas úteis na modulação da contratilidade do músculo esquelético, composições farmacêuticas e uso dos compostos
BR112013016856A2 (pt) composto, uso de um composto, composição farmacêutica e produto farmacêutico
CY1113395T1 (el) Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη
ATE541839T1 (de) Pyrrolidiniumderivate als m3-muskarinische rezeptoren
EA201070588A1 (ru) Производные 1,2,3-триазола для применения в качестве ингибиторов стеароил-соа десатуразы
PH12019502562A1 (en) N-substituted indole derivatives
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
MX2019005706A (es) Inhibidores de la tirosina quinasa de bruton.
AR047606A1 (es) 4-oxobenzonitrilos como moduladores de receptores de androgenos,composiciones farmaceuticas que los contienen y usos
EA200901381A1 (ru) Производные азетидина и их применение в качестве антагонистов простагландина е2
ATE450262T1 (de) Harnstoff-derivate als calcium-rezeptor- modulatoren
MA38854A1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität